Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    Cad106
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
Condition: Alzheimer's Disease
Intervention: Biological: CAD106
2 Completed To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
Condition: Alzheimer Disease
Intervention: Biological: CAD106
3 Completed Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients
Condition: Alzheimer's Disease
Interventions: Biological: Placebo;   Biological: CAD106
4 Completed To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
Condition: Alzheimer Disease
Intervention: Biological: CAD106
5 Recruiting A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: CAD106 Immunotherapy;   Other: Placebo to CAD106;   Drug: CNP520;   Other: Placebo to CNP520
6 Completed Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Interventions: Biological: CAD106;   Drug: Placebo
7 Completed Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.
Condition: Alzheimer Disease
Interventions: Biological: Placebo;   Biological: CAD106

Indicates status has not been verified in more than two years